Therapeutic Area

Immunotherapy

Therapeutic area intelligence for Immunotherapy with 13 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 13
Catalysts: 0
Companies: 4

Companies

AstraZeneca →

Bristol-Myers Squibb →

Merck →

Roche →

Assets

Recent signals(13)

ClinicalJune 21, 2026

Study Optimizes Immunotherapy for Pancreatic Adenocarcinoma Treatment

The study identifies opsonization and timing as critical factors influencing the efficacy of immunotherapy in pancreatic adenocarcinoma.

ClinicalJune 20, 2026

FCGR2B Targeting Enhances Anti-Tumor Activity of Macrophages in Melanoma

FCGR2B knockdown in tumor-associated macrophages enhances their anti-tumor capabilities by reducing M2 polarization and improving phagocytosis.

ClinicalJune 20, 2026

Study on COVID-19 Vaccine Safety in Cancer Immunotherapy Patients Launched

A retrospective study is being initiated to evaluate the safety of COVID-19 vaccines in patients undergoing immunotherapy for cancer.

ClinicalJune 19, 2026

Advancements in NK Cell-Based Immunotherapy for Cancer Treatment

NK cell therapies are advancing with promising safety profiles and clinical applicability, leveraging various innovative strategies.

ClinicalJune 18, 2026

Study on Treatment Patterns for Nivolumab in Community Oncology Settings

The study will analyze treatment patterns and safety events associated with nivolumab administration routes in cancer patients.

ClinicalJune 18, 2026

Nivolumab Phase III Trial for High Risk Stage II-IIIB Anal Cancer Initiated

A phase III trial is underway to evaluate the efficacy of nivolumab following combined modality therapy in high risk stage II-IIIB anal cancer patients.

ClinicalJune 18, 2026

Phase III Trial of Nivolumab Post-Surgery in Non-Small Cell Lung Cancer

A phase III trial is evaluating the efficacy of nivolumab following surgery and chemotherapy in patients with stage IB-IIIA non-small cell lung cancer.

ClinicalJune 17, 2026

Phase III Trial of Pembrolizumab with Chemotherapy in Non-small Cell Lung Cancer

The ALCHEMIST trial is evaluating the efficacy of adding pembrolizumab to standard chemotherapy in resected non-small cell lung cancer.

ClinicalJune 17, 2026

Phase III Trial of Durvalumab with Chemotherapy in Stage II-III Breast Cancer

A phase III trial is evaluating the addition of durvalumab to standard chemotherapy in patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

CompetitiveJune 16, 2026

Merck Reports Promising Long-Term Data for KEYTRUDA and Intismeran in Oncology at ASCO 2026

Five-year follow-up data from KEYNOTE-942 show the potential of intismeran autogene in combination with KEYTRUDA for high-risk melanoma. Additionally, KEYNOTE-522 results indicate a continued survival benefit for high-risk early-stage TNBC patients.

RegulatoryJune 16, 2026

Imfinzi Gains US Approval for Early Bladder Cancer with BCG Combination

Imfinzi has been approved in the US as the first immunotherapy combination for BCG-naïve, high-risk non-muscle-invasive bladder cancer, showing a 32% reduction in disease recurrence, progression, or death.

RegulatoryJune 11, 2026

FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer

The FDA has accepted Roche's sBLA for Tecentriq plus chemotherapy in stage III dMMR/MSI-H colon cancer, with a decision expected by October 9, 2026.

RegulatoryJune 11, 2026

FDA grants Priority Review for Roche’s Tecentriq in stage III colon cancer

The FDA has accepted Roche's sBLA for Tecentriq in combination with chemotherapy for stage III dMMR/MSI-H colon cancer, with a decision expected by October 9, 2026.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.